Medical Technology · us
Assessing Dementia Risk Within Five Years: NeuroXT’s AI Software for Cognitive Impairment Receives FDA Clearance
NEXT-Cue integrates brain MRI, cognitive assessments, and demographic data to help physicians assess disease progression in patients with mild cognitive impairment. Following U.S. marketing clearance, its predictive performance and benefits in actual care remain key areas for evaluation.
For people diagnosed with mild cognitive impairment, whether they will progress to dementia over the next few years is a question shared by patients, families, and physicians, alongside their current cognitive performance. On October 20, NeuroXT announced that its artificial intelligence software, NEXT-Cue, had received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) to help assess the likelihood that these patients will progress to Alzheimer’s dementia within five years.
NEXT-Cue integrates brain magnetic resonance imaging (MRI), cognitive assessments, and demographic data to provide physicians with information predicting disease progression. It is intended for follow-up assessments of patients already diagnosed with mild cognitive impairment. Five years is the period covered by the prediction and should not be interpreted as a deadline by which an individual patient will inevitably develop dementia.
Records listed by Innolitics, a medical device regulatory information platform, show that NEXT-Cue’s 510(k) number is K261805, with an FDA decision date of October 8, 2026. It is classified as a Class II medical device under 21 CFR 882.1454. This type of software is available by prescription only and is intended as an aid to clinical assessment. It cannot serve as the sole basis for diagnosis or prognosis. This also sets boundaries for how physicians interpret and use its output.
Currently verifiable materials concerning this development do not yet provide sufficient validation details to fully evaluate NEXT-Cue’s performance, including the number of participants, sources of training and test data, independent validation design, and metrics such as sensitivity and specificity. At this stage, therefore, what can be confirmed is the regulatory milestone and intended use. These materials do not yet allow a comparison of its accuracy with existing clinical assessment methods or a determination of its applicability across different patient populations and healthcare institutions.
Commercial plans are also moving forward following clearance. Diagnostic Imaging and South Korea’s Pharmaceutical News reported that NeuroXT plans to establish clinical use cases at major U.S. healthcare institutions and accelerate commercialization. Pharmaceutical News also cited company plans indicating that the approval process with South Korea’s Ministry of Food and Drug Safety is underway, with a target of launching commercialization in South Korea in early 2027. This remains a timeline put forward by the company.
As NEXT-Cue moves from marketing clearance toward becoming part of routine care, it will need to demonstrate whether its predictive information can perform consistently in real clinical settings and whether physicians can use it to improve patient management. For patients, the value of risk assessment ultimately depends on how it helps them understand disease progression, arrange follow-up, and discuss care, beyond the prediction result itself.